Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials

Abstract Background Henoch-Schönlein purpura nephritis (HSPN) is listed as the most common secondary glomerular diseases among children. Approximately 15 to 20% of children eventually could develop into chronic renal failure. Chinese patent herbal medicine Huaiqihuang (HQH) has been widely used in c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xue Xue, Xue-han Liu, Chun-li Lu, Xin-yan Jin, Qiang Liu, Xiao-qin Wang, Jian-ping Liu
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Chinese patent herbal medicine Huaiqihuang Henoch-Schonlein purpura nephritis Children Randomized controlled trials Systematic review Other systems of medicine RZ201-999
Acceso en línea:	https://doaj.org/article/2194504f12754f6bb4f3e874ba44b975
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2194504f12754f6bb4f3e874ba44b975
record_format	dspace
spelling	oai:doaj.org-article:2194504f12754f6bb4f3e874ba44b9752021-11-14T12:38:01ZChinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials10.1186/s12906-021-03415-x2662-7671https://doaj.org/article/2194504f12754f6bb4f3e874ba44b9752021-11-01T00:00:00Zhttps://doi.org/10.1186/s12906-021-03415-xhttps://doaj.org/toc/2662-7671Abstract Background Henoch-Schönlein purpura nephritis (HSPN) is listed as the most common secondary glomerular diseases among children. Approximately 15 to 20% of children eventually could develop into chronic renal failure. Chinese patent herbal medicine Huaiqihuang (HQH) has been widely used in children with HSPN. This study aimed to evaluate the effectiveness and safety of HQH for HSPN in children, so as to provide evidence for clinical use. Methods Randomized controlled trials (RCTs) on HQH for HSPN in children were searched in eight Chinese and English databases from their inception to December 2020. We included children with HSPN received HQH combined with conventional medicine. Cochrane “Risk of bias” tool was used to assess methodological quality, and “Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach” to summarize the certainty of evidence for main findings. Effect estimates were presented as risk ratio (RR), mean difference (MD) or standardized mean difference (SMD) with 95% confidence interval (CI) in meta-analyses using RevMan 5.3. Data not suitable for statistical pooling were synthesized qualitatively. Results In total seven RCTs were identified. Compared with conventional medicine alone, HQH plus conventional medicine showed the better effect in improving clinical cure rate (RR 1.58; 95%CI 1.17 to 2.14; n = 6) and total effective rate (RR 1.34; 1.16 to 1.54; n = 6); reducing urine sediment erythrocyte count (MD -9.23; − 10.76 to − 7.69; n = 3) and urine β2 micro-globulin level (MD -0.09; − 0.12 to − 0.06; n = 2). No serious adverse event was recorded in all included trials. Conclusions Limited evidence showed HQH combined with conventional medicine had a beneficial effect for children with HSPN, and the side effects were mild. HQH may be a promising complementary therapy. However, long term follow-up, high quality and multicenter RCTs are required to confirm the findings.Xue XueXue-han LiuChun-li LuXin-yan JinQiang LiuXiao-qin WangJian-ping LiuBMCarticleChinese patent herbal medicineHuaiqihuangHenoch-Schonlein purpura nephritisChildrenRandomized controlled trialsSystematic reviewOther systems of medicineRZ201-999ENBMC Complementary Medicine and Therapies, Vol 21, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Chinese patent herbal medicine Huaiqihuang Henoch-Schonlein purpura nephritis Children Randomized controlled trials Systematic review Other systems of medicine RZ201-999
spellingShingle	Chinese patent herbal medicine Huaiqihuang Henoch-Schonlein purpura nephritis Children Randomized controlled trials Systematic review Other systems of medicine RZ201-999 Xue Xue Xue-han Liu Chun-li Lu Xin-yan Jin Qiang Liu Xiao-qin Wang Jian-ping Liu Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials
description	Abstract Background Henoch-Schönlein purpura nephritis (HSPN) is listed as the most common secondary glomerular diseases among children. Approximately 15 to 20% of children eventually could develop into chronic renal failure. Chinese patent herbal medicine Huaiqihuang (HQH) has been widely used in children with HSPN. This study aimed to evaluate the effectiveness and safety of HQH for HSPN in children, so as to provide evidence for clinical use. Methods Randomized controlled trials (RCTs) on HQH for HSPN in children were searched in eight Chinese and English databases from their inception to December 2020. We included children with HSPN received HQH combined with conventional medicine. Cochrane “Risk of bias” tool was used to assess methodological quality, and “Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach” to summarize the certainty of evidence for main findings. Effect estimates were presented as risk ratio (RR), mean difference (MD) or standardized mean difference (SMD) with 95% confidence interval (CI) in meta-analyses using RevMan 5.3. Data not suitable for statistical pooling were synthesized qualitatively. Results In total seven RCTs were identified. Compared with conventional medicine alone, HQH plus conventional medicine showed the better effect in improving clinical cure rate (RR 1.58; 95%CI 1.17 to 2.14; n = 6) and total effective rate (RR 1.34; 1.16 to 1.54; n = 6); reducing urine sediment erythrocyte count (MD -9.23; − 10.76 to − 7.69; n = 3) and urine β2 micro-globulin level (MD -0.09; − 0.12 to − 0.06; n = 2). No serious adverse event was recorded in all included trials. Conclusions Limited evidence showed HQH combined with conventional medicine had a beneficial effect for children with HSPN, and the side effects were mild. HQH may be a promising complementary therapy. However, long term follow-up, high quality and multicenter RCTs are required to confirm the findings.
format	article
author	Xue Xue Xue-han Liu Chun-li Lu Xin-yan Jin Qiang Liu Xiao-qin Wang Jian-ping Liu
author_facet	Xue Xue Xue-han Liu Chun-li Lu Xin-yan Jin Qiang Liu Xiao-qin Wang Jian-ping Liu
author_sort	Xue Xue
title	Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials
title_short	Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials
title_full	Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials
title_fullStr	Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials
title_full_unstemmed	Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials
title_sort	chinese patent herbal medicine huaiqihuang for henoch-schonlein purpura nephritis in children: a systematic review of randomized controlled trials
publisher	BMC
publishDate	2021
url	https://doaj.org/article/2194504f12754f6bb4f3e874ba44b975
work_keys_str_mv	AT xuexue chinesepatentherbalmedicinehuaiqihuangforhenochschonleinpurpuranephritisinchildrenasystematicreviewofrandomizedcontrolledtrials AT xuehanliu chinesepatentherbalmedicinehuaiqihuangforhenochschonleinpurpuranephritisinchildrenasystematicreviewofrandomizedcontrolledtrials AT chunlilu chinesepatentherbalmedicinehuaiqihuangforhenochschonleinpurpuranephritisinchildrenasystematicreviewofrandomizedcontrolledtrials AT xinyanjin chinesepatentherbalmedicinehuaiqihuangforhenochschonleinpurpuranephritisinchildrenasystematicreviewofrandomizedcontrolledtrials AT qiangliu chinesepatentherbalmedicinehuaiqihuangforhenochschonleinpurpuranephritisinchildrenasystematicreviewofrandomizedcontrolledtrials AT xiaoqinwang chinesepatentherbalmedicinehuaiqihuangforhenochschonleinpurpuranephritisinchildrenasystematicreviewofrandomizedcontrolledtrials AT jianpingliu chinesepatentherbalmedicinehuaiqihuangforhenochschonleinpurpuranephritisinchildrenasystematicreviewofrandomizedcontrolledtrials
_version_	1718429095077871616

Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials

Ejemplares similares